Topic Hubs
AI drug discovery: News, analysis and interviews
Antibody-drug conjugates: The next wave of targeted cancer drugs
Biopharma M&A and dealmaking: Who’s buying and why
Biopharma people moves: CEO changes, executive hires, board positions
Biotech IPOs: Tracking the market for new public offerings
Biotech venture funding: Who’s raising and where the money is going
Cell and gene therapy manufacturing: Scaling the next frontier
China biotech: Licensing deals and the Biosecure Act
CRISPR and gene editing: The push for in vivo therapies
Drug pricing and the IRA: Tracking the government's negotiation power
FDA policy and drug approvals: What’s changing for biopharma
GLP-1 drugs: The obesity pipeline race and what's next
Channels
All News
In Focus
Special
AI
Bioregnum
Biotech Voices
Cell/Gene Tx
China
Coronavirus
Deals
Diagnostics
Discovery
FDA+
Financing
Health Tech
Law
Letters to the Editor
Manufacturing
Marketing
Nikkei Biotechnology
Opinion
Outsourcing
Peer Review
People
Pharma
R&D
Startups
Weekly
Webinars
Signal
More
Work at Endpoints
Biopharma Jobs
Letter to Editors
Editorial Standards
IPO Tracker
Webinars
Events
Sponsored Posts
Advertise
Privacy Policy
Endpoints Merch
About Us
Help
SIGN UP
LOG IN
Deals channel feed
Are pharma megadeals dead? Smaller targets take priority amid hunt for blockbusters
Yesterday
Pharma
M&A isn’t just for big pharma. A diverse group of mid-size companies are stepping up dealmaking
Yesterday
Financing
Pfizer and Arvinas give disappointing breast cancer drug to Rigel
4 days ago
Bayer to make 'careful but aggressive' return to pharma M&A, CEO says
4 days ago
Pharma
Bristol Myers joins Hengrui party in 13-asset deal worth up to $15.2B
4 days ago
China
Pharma
Angelini fortifies neurology portfolio with $4.1B buyout of Catalyst
Last week
Pharma
GSK goes to China for $1B siRNA deal in Arrowhead's obesity lane
Last week
China
Pharma
Bayer dips toes back into pharma M&A to buy Perfuse Therapeutics
Last week
Pfizer's Albert Bourla on mega-merger prospects: 'No'
Last week
R&D
Pharma
Updated: Madrigal extends MASH deal streak with Arrowhead drug that J&J didn't want
Last week
Pharma
UCB bets $2B on Candid's T cell engager ambitions
Last week
China
Acelyrin founder Shao-Lee Lin emerges at Cue, as it becomes latest to license from China
3 weeks ago
People
China
Post-Hoc Live: The GLP-1 pill battle, biotech M&A, patent cliffs and more
3 weeks ago
R&D
After Apellis deal, Biogen looks to fill early-stage pipeline
3 weeks ago
R&D
Chiesi signs $1.9B deal to acquire KalVista and its approved drug
3 weeks ago
Pharma
MPM has collected three China drugs so far for its ‘best of both worlds’ strategy
3 weeks ago
Startups
China
BeOne joins the VEGF competition, but with a trispecific antibody
3 weeks ago
R&D
Updated: AbbVie flirts with popular pan-RAS field in up to $1.45B option to acquire Kestrel
3 weeks ago
Pharma
Lilly strikes second partnership this year for recombinase-based gene editing
3 weeks ago
Cell/Gene Tx
Lilly announces a new cancer deal, paying Ajax up to $2.3B for JAK inhibitor
3 weeks ago
Sun Pharma to buy Organon for $11.75B in major portfolio expansion
3 weeks ago
Pharma
Rigel loses Lilly alliance in pharma industry's latest RIPK exit
4 weeks ago
R&D
Pharma
Soleno sold at a discount to Neurocrine due to dwindling European prospects
4 weeks ago
Pharma
One of Kelonia's key investors will clear a 45-fold return on startup's sale to Lilly
4 weeks ago
1
2
3
4
Next page
Last page
Confirm Profile
Full Name
Email
Company
Job Title
State
{@!--CONSENT--!@}
Submit
